|
|
|
|
::: A.P. Pharma Receives FDA Complete Response Letter for APF530
REDWOOD CITY, Calif.--(BUSINESS WIRE)--A.P.Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New...
|
|
|
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Financial Results
SAN DIEGO, March 15 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc.( NASDAQ:CADX) , a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
Let the jobs come to you!Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug ...
|
|
|
ADVENTRX Receives Brand Name Acceptance for ANX-530
SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc.(NYSE Amex: ANX) today announced that the U.S. Food and Drug Administration (FDA) has accepted the proposed proprietary name 'Exelbine(TM)' for the Company's product...
|
|
|
US FDA accepts NDA for once-daily fixed dose combo Onglyza & extended release Metformin for type 2 diabetes mellitus in adults
Bristol-Myers Squibb Company and AstraZeneca announced that the US Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of Onglyza (saxagliptin), a...
|
|
|
News and FDA Updates for AdvanSource (NYSE:ASB), A.P. Pharma (Nasdaq:APPA), Baxter (NYSE:BAX)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of...
|
|
|
News and FDA Updates for AdvanSource (NYSE:ASB), A.P. Pharma (Nasdaq:APPA), Baxter (NYSE:BAX)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical...
|
|
|
Somaxon Announces FDA Approval Of Silenor(R) (doxepin) For The Treatment Of Insomnia
Somaxon Pharmaceuticals, Inc.(Nasdaq: SOMX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor (doxepin) for the treatment of insomnia characterized by...
|
|
|
U.S. Food And Drug Administration Accepts New Drug Application For Once-Daily Fixed Dose Combination Of Onglyz
Bristol-Myers Squibb Company(NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S.Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose...
|
|
|
A.P. Pharma (APPA) Receives Complete Response Letter from U.S. FDA for APF530 NDA
Pharma, Inc.(NASDAQ: APPA) today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for APF530 in the prevention of both...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
REDWOOD CITY, Calif.--(EON: Enhanced Online News)--A.P.Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency)...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
REDWOOD CITY, Calif.--(BUSINESS WIRE)--A.P.Pharma, Inc. (Nasdaq:APPA - News), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
(BUSINESS WIRE) -- A.P.Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug ...
|
|
|
FDA Denies Approval of A.P. Pharma, Inc. (APPA) Nausea Drug
(BUSINESS WIRE) -- /quotes/comstock/15*!appa/quotes/nls/appa (APPA 0.93, -1.13, -54.85%) , a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S.Food and Drug Administration (FDA or Agency)...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
(BUSINESS WIRE) -- A.P.Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug ...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
REDWOOD CITY, Calif.Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug ...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
BusinessWire - A.P.Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug ...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
- REDWOOD CITY, Calif.--(BUSINESS WIRE)--A.P.Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
Pharma, Inc.(Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
Pharma, Inc.(Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
- REDWOOD CITY, Calif.--(BUSINESS WIRE)--A.P.Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
- Company to host conference call at 9:00 a.m.ET on Friday, March 19, 2010 - REDWOOD CITY, Calif.--(BUSINESS WIRE)--A.P. Pharma, Inc. (Nasdaq:APPA - News), a specialty pharmaceutical company, today announced that it received a Complete Response...
|
|
|
News and FDA Updates for Amylin (Nasdaq:AMLN), Eli Lilly (NYSE:LLY), Alkermes (Nasdaq:ALKS)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
- REDWOOD CITY, Calif.--(BUSINESS WIRE)-- A.P.Pharma, Inc. (Nasdaq: APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its ...
|
|
|
A.P. Pharma Receives FDA Complete Response Letter for APF530
Pharma, Inc.(Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for...
|
